SCHEMBL4735977

SCHEMBL4735977

O=c1c2c(F)cccc2nc(-c2ccc(F)cc2)n1NCc1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 4/20 0.38
EGFR P00533 1/20 0.38
HTT P42858 1/20 0.37
F2RL1 P55085 1/20 0.36
CYP3A4 P08684 1/20 0.36
TP53 P04637 1/20 0.36
KCNH2 Q12809 1/20 0.36
GRM2 Q14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233963 0.91 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4236185 0.85 SMN1; SMN2 (0.67) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4195763 0.82 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4201369 0.79 SMN1; SMN2 (0.44) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4201370 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4241365 0.78 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4242353 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4345893 0.77 SMN1; SMN2 (0.42) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4239901 0.77 SMN1; SMN2 (0.54) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4244202 0.77 SMN1; SMN2 (0.57) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 SMN1; SMN2 4767/4885MAPT 4430/4885NPSR1 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.